Tiger Brokers

BUZZ-Greenwich LifeSciences surges as FDA clears supplies for breast cancer trial

Reuters
Jan 22
BUZZ-Greenwich LifeSciences surges as FDA clears supplies for breast cancer trial

** Shares of cancer therapy developer Greenwich LifeSciences GLSI.O rise 14% to $25.53 premarket

** Co says U.S FDA cleared first batch of GP2 vials for use in a late‑stage breast cancer study

** GP2 is an experimental immunotherapy aimed at preventing breast cancer from returning after standard treatment

** GLSI says the approval reduces manufacturing‑related risks ahead of a potential U.S. marketing application

** Trial is enrolling at 40 U.S. sites and may expand to as many as 150 globally; more than 1,000 patients screened so far, co says

** Co says early data shows an estimated 80% reduction in cancer recurrence, though findings are preliminary

** Shares up ~87% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10